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Wilms tumor is the most frequent pediatric renal malignancy, and its usual presentation is an abdominal mass or hematuria.
Unusual presentations have also been reported, such as paraneoplastic syndromes (acquired von Willebrand disease, sudden
death due to pulmonary embolism, and Cushing syndrome). &ese conditions can precede, occur concomitantly, or present in a
later phase of tumor development. Precocious puberty, as paraneoplastic endocrine syndrome, has already been described in
children with malignant tumors (brain, gonadal, adrenal tumors, and hepatoblastoma). However, little is known about central
precocious puberty, as paraneoplastic manifestation of nephroblastoma or secondary to its specific chemotherapy. Here, we report
a case of Wilms tumor and simultaneous precocious puberty in a 5-year-old girl. &e initial diagnosis was premature telarche, but
the clinical and biological pubertal progression changed our diagnosis to idiopathic central precocious puberty. Chemotherapy
and nephrectomy were well tolerated, and we began treatment with a gonadotropin-releasing hormone agonist which showed
favorable outcomes over the short term. We highlight the need for early diagnosis and work-up in all patients of precocious
puberty, in order to institute timely management.
1. Introduction
Premature telarche (PT), a benign condition in girls younger
than 8 years of age, defines an isolated breast development,
without other signs of puberty.&e diagnosis is usually made
clinically and does not require biochemical or radiological
tests. &e most consistent aspect of PTmanagement requires
serial monitoring of the patient to ensure the continued
absence of other sexual characteristics. &e spontaneous
regression of breast enlargement is usually the main evo-
lution rule. After this self-limited event, puberty usually
occurs and progresses physiologically.
However, it is possible that PT progresses to precocious
puberty (PP), with pubertal initiation before the age of
8 years in girls and 9 years in boys. &e incidence of PP was
recently estimated to be 0.2% in girls and 0.05% in boys [1].
Approximately 90% of girls and 25–60% of boys, with PP
have an idiopathic cause [2, 3]. &e organic etiology is more
frequently in boys and includes congenital and acquired
cranial and extracranial lesions.
PP is one of the most common endocrine-related
manifestations of neoplasia in pediatric patients. Other
systemic or endocrine manifestations, globally referred to as
paraneoplastic syndrome, include hypercalcemia, in-
appropriate antidiuretic hormone secretion, ectopic adre-
nocorticotrophic hormone secretion, and hypoglycemia.
Endocrine abnormalities can also appear subsequently, after
the neoplasia has been treated, associated with drugs or
radiation.
Herein, we present the case of a child with Wilms tumor
and concomitant PTwho progressed to central PP (CPP). In
addition, we provide a review of the literature relating to
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neoplasia-associated puberty and paraneoplastic manifes-
tations of renal tumors.
2. Case Presentation
A previously healthy 5-year-old girl of African origin pre-
sented to the Emergency Department (ED) with macro-
scopic hematuria appeared 24 hours before presentation and
isolated abdominal pain for one month previously. &ere
was no history of fever, vomiting, urinary or systemic
symptoms, weight loss, or abdominal trauma.
&e patient had no significant medical history, in par-
ticular, head injuries such as trauma, hemorrhage, or in-
fection, and did not take any medications. Family history
was unremarkable, with no antecedents of neoplasm or
precocious puberty. Her mother was not taking any con-
traceptive hormonal medications, and there was no history
of any other source of exposure to hormonal drugs.
On physical examination, the child appeared well. Her
anthropometric parameters were as follows: weight 21 kg
(50th percentile); height 117 cm (50–75th percentile).
Her vital signs were normal, except for blood pressure at
130/90mmHg (>99th percentile for sex and height). She had
neither dysmorphic features nor skin lesions (café-au-lait
spots, facial acne). On abdominal examination, we palpated
a mass, measuring 6 cm with regularly margins in the right
upper quadrant. &ere was no central nervous system
dysfunction (headache, vomiting or visual abnormalities).
She had bilateral, symmetrical nontender enlargement of
breast buds corresponding to stage 2 of the Tanner classi-
fication. &ere was no pubic or axillary hair, and her thyroid
was normal on clinical inspection.
Laboratory work-up in the ED included a complete
blood count, metabolic panel, and urinalysis. Her hema-
tologic and basic metabolic panel, serum electrolytes, and
liver and renal function tests were normal. Urinalysis
confirmed hematuria. &e child underwent an ultrasonog-
raphy, which revealed a well-circumscribed heterogeneous
echogenic mass, measuring 9.2× 9.5 cm, in the right renal
fossa. With suspicion of Wilms tumor, the child was ad-
mitted into the Oncology Department. On abdominal and
pulmonary computerized tomography (CT), a high suspi-
cion of nephroblastoma was made. Histological examination
confirmed the diagnosis of intermediary-risk nephro-
blastoma stage I.
&e first endocrine work-up revealed a normal thyroid
function and prepubertal gonadotropin levels (see Table 1).
Ultrasonography excluded ovarian and adrenal masses and
showed infantile ovaries and uterus. Bone age was not
performed. &e endocrine diagnosis was bilateral PT.
&e International Society of Pediatric Oncology (SIOP)
2001 chemotherapy protocol (dactinomycin/vincristine) was
commenced, with complete excision of the tumor performed
4weeks later. Additional chemotherapy cycles were pro-
vided after surgery, for a total duration of 3months. &e
clinical tolerance and response were excellent, without any
side effects or signs of residual tumor.
A second endocrine assessment was performed at the
end of chemotherapy. Surprisingly, we identified an
accelerated linear growth (a gain of 3 cm in 4months) in the
context of rapid breast development (passage from stage 2 to
stage 3 over 4months) with no axillary or pubic hair. &e
second hormonal work-up found an activated pituitary-
gonadal axis (Table 1) along with advanced skeletal matu-
ration and ultrasound signs of uterine hormonal impreg-
nation. A gonadotropin-releasing hormone analog (GnRHa)
stimulation test was carried out and showed a pubertal
response, confirming gonadotropin-dependent puberty
(Table 1).
Magnetic resonance imaging (MRI) of the brain showed
a morphologically normal pituitary, but of pubertal size
(pituitary height of 6mm andmarked convexity of the upper
surface) and no congenital or acquired lesions in the pineal
or hypothalamic-optic region (Figure 1). Human chorionic
gonadotropin (hCG) levels (repeated twice at different time
points) were normal. hCG-secreting tumor was considered
as potential etiology of PP, but this diagnosis was excluded
on both biological (high LH and FSH levels, normal hCG)
and radiological arguments (no tumor in liver, mediasti-
num, ovaries, or CNS).
&e definitive diagnosis of idiopathic CPPwasmade, and
we began treatment with GnRHa (11.25mg every 3months,
intramuscularly). Six months later, we noted a reassuring
clinical evolution, with partial regression of breast devel-
opment, reduction in growth velocity (2 cm/6months), and
increasingly random LH level at 3.4 IU/L. Recently, a pro-
spective study [4] showed that this biological evolution, with
incomplete suppression of LH levels, is common in children
with CPP under treatment. In a patient with a favorable
clinical response (neither clinical pubertal progression, nor
an advancement of bone age), this biological evolution
should not be interpreted as indicative of treatment failure.
&e global evolution of our patient, from oncological
diagnosis up to 6months after the beginning of CPP
treatment, is depicted in Table 1.
3. Discussion
At the time of oncological diagnosis, our patient presented
with classical PT. Her subsequent evolution, with accelerated
height velocity (3 cm/4months) in the context of somatic
stress related to nephroblastoma treatment (nephrectomy
and chemotherapy), was the first finding signaling the
evolution to PP.
PTcases progressing to PP are described in the literature,
with a prevalence of 9 to 14% [5, 6]. Neither clinical nor
biological findings were suggestive of a progression although
a recent retrospective study analyzing the etiology, MRI
abnormalities, and growth velocity of girls with PP found
that growth velocity can effectively differentiate PP from PT
in girls aged 6–8 years [7]. In another study [8], similar
elements were found, with a higher height and bone age/
chronological age ratio as risk factors for progression to PP.
&e diagnosis of PP requires a clinical, biological, and
radiological evaluation. A detailed personal and family
history and a complete physical examination including the
assessment of linear growth and secondary sexual features
(breast development in girls and testis measurement in boys,
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and pubic hair development in both sexes) and their clas-
sification on the basis of the Marshall and Tanner are
necessary information. Bone age (typically advanced) and
pelvic ultrasound (uterine and ovarian dimensions) are well
correlated. &e diagnostic value of basal LH is variable, and
in this circumstance, the gold standard of the biochemical
diagnosis is based on the assessment of gonadotropins,
mainly LH, after stimulation with GnRHa. A peak stimu-
lated LH of >5 IU/L along with an LH/FSH ratio of ≥2 are
consistent with the diagnosis of CPP [9]. However, some
challenges in the hormonal assessment of children with
sexual precocity at the time of diagnosis still remain.
Wilms tumor is known to be associated with paraneo-
plastic systemic findings (hypertension, erythrocytosis, and
acquired von Willebrand disease) and endocrine manifes-
tations including hypercalcemia, Cushing syndrome, and
hypoglycemia [10–12].
Given the troublesome presentation of our case, we
reviewed the literature on neoplasm-related PP and effects of
cancer therapy upon pubertal activation. Brain, gonadal,
adrenal tumors, and hepatoblastoma are the most frequent
tumors that may be associated with PP [13].
CNS tumors can disrupt hypothalamic and pituitary
function, with secondary CPP. &e most common tumors
are hypothalamic (hamartomas, gliomas, and germinomas),
chiasmatic (gliomas), and pineal (parenchymal tumors and
germinomas) [14]. Ependymomas (located in the lateral
posterior fossa) often cause obstructive hydrocephalus that
leads to detrimental effects within the hypothalamic region,
including precocious pubertal onset. A variety of mecha-
nisms have been reported to activate the hypothalamus/
pituitary axis, but these have yet to be fully elucidated. One
of the first pathophysiological hypotheses was related to
tumor location, which is seen as a major contributing factor
Table 1: Patient’s evolution.




Tanner stage II-breast development
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Height 120 cm (+3 cm/4 months)















LH (40min post 100 µg
triptorelin injection, sc) 13 IU/L
FSH (40min after 100 µg triptorelin




heterogeneous echogenic mass of
9.2× 9.5 cm in right renal fossa
Bone age—8 years
Pelvic US—normal ovary size and
morphology, enlarged uterus with
maximum length of 45mm
Brain MRI—Pituitary height of 6mm
and marked convexity of the upper
















LH: luteinizing hormone; FSH: follicular stimulating hormone; sc: subcutaneous; US: ultrasound; hCG: human chorionic gonadotropin; SIOP: International
Society of Pediatric Oncology; PT: premature telarche; CPP: central precocious puberty; GnRHa: gonadotrophin releasing hormone analog.
Figure 1: Coronal post-Gadolinium brain MRI image showing a
normal pituitary morphology, of pubertal size, with marked upper
surface convexity.
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in the premature activation of the hormonal axis [14]. More
recently, a functional hypothesis, stating that tumor cells can
produce hormones or substances which subsequently in-
terfere with physiological GnRH secretion and GnRH
neuron differentiation, has become more accepted. In boys,
germinal cell tumors that produce hCG, a glycoprotein in
which the α-subunit is identical to that of LH, induce
precocious puberty due to cross reaction between hCG and
the LH receptor. &e clinical profile of this condition results
in pubertal changes to the external genitalia, but with less
testicular enlargement (secondary to the lack of Sertoli cell
stimulation from FSH). &e biological profile includes low
levels of LH/FSH and high levels of testosterone due to the
stimulatory effect of hCG on the LH receptor in the testes.
Final diagnosis is made by measuring serum and cerebro-
spinal fluid hCG levels. Pediatric germ-cell tumors that
induce this type of gonadotropin-dependent precocious
puberty can also be mediastinal (particularly in Klinefelter
syndrome) [15, 16], hepatic, or gonadal.
In females, hCG-secreting tumors can induce PP by
several possible mechanisms, including the cosecretion of
hCG and estradiol, low FSH activity of the very high hCG,
and high tumoral aromatase activity for some cranial dys-
germinomas [17–19].
&e risk of organic pathology, particularly intracranial, is
much higher in boys than in girls [20]. Age seems to be an
important predictor of cerebral abnormalities (the younger
the child, the higher the risk), and such lesions can be
evaluated efficiently with MRI imaging.
Cranial radiation therapy (CRT) for cerebral tumors,
with high radiation doses, has direct effects on GnRH with
clinical and biological CPP. CPP is among themost common
complications that can occur following CNS tumors and/or
CRT affecting the hypothalamus/pituitary [21]. &e risk of
developing early puberty is greater for younger children
[22], and the proposed mechanism of hypothalamic/pitui-
tary dysfunction caused by irradiation is the disinhibition of
cortical influences upon the hypothalamus.
Other types of tumors that are able to induce PP include
hepatoblastomas and gonadal neoplasia. A hepatoblastoma
is a hepatic type of tumor which can produce hCG.&is form
of tumor is not uncommonly associated with PP in males
(testicular stimulation by hCG). Some tumor cells are also
able to secrete testosterone [22]. Gonadal tumors are as-
sociated with PP due to excessive sex hormone secretion by
the organ containing the tumor, or the tumor’s tissue of
origin. For example, adrenocortical tumors are associated
with PP because of excessive androgen production [13].
An interesting point to consider is whether the CPP in
our case represented a coincidental finding. We performed a
full review of the published literature indexed in PubMed up
to January 2019 regardingWilms tumor and puberty. Search
terms included “Wilms tumor,” “paraneoplastic syndrome,”
and “precocious puberty.” Our search failed to identify
existing reports relating to the coexistence of Wilms tumor
and CPP.
It is possible that the pathogenesis of CPP could be
related to the concomitant effect of chemotherapy along
with functional alterations in the HPG axis, but none of the
existing literature described similar circumstances. Che-
motherapy could cause some anterior pituitary dysfunction
in the survivors of childhood cancer, with hormonal de-
ficiencies but not activation of the hypothalamic/pituitary
axis. Alkylating agents, such as cyclophosphamide, lomus-
tine, and procarbazine, are known to cause premature
ovarian insufficiency and can indirectly affect pituitary
function, but this adaptive pituitary response is not con-
sidered a disease [23].
Collating data from the literature review relating to the
proposed pathophysiological mechanisms underlying par-
aneoplastic syndrome and neoplasia-induced pubertal ac-
tivation and considering this alongside our patient’s clinical
evolution, we finally established that the association between
Wilms tumor and CPP was purely coincidental.
4. Conclusion
We report a case of PTwith rapid progression to CPP in a 5-
year-old girl with a concomitant Wilms tumor. Our ob-
servations may shed light on the necessity to diagnose PP
early in every child irrespective of the presenting illness. A
complete clinical examination and prompt referral to a
pediatric endocrinologist for specific work-up and treatment
are helpful in limiting early and late long-term health im-
plications (short stature, psychosocial outcomes, metabolic
and cardiac events, and the risk of breast cancer
development).
We therefore recommend that when faced with PP in a
child with a concomitant tumor, the diagnosis of para-
neoplastic or neoplasia-associated PP should be discussed.
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